Why the study?
Extended prophylaxis of VTE in acutely ill medical patients requires evaluation of safe and effective oral anticoagulant options.
Does betrixaban prevent VTE in acutely ill medical patients?
Does betrixaban prevent VTE in acutely ill medical patients?
Betrixaban is an effective and safe oral factor Xa inhibitor for extended VTE prophylaxis in acutely ill medical patients transitioning from hospital to home.
Answers are grounded in this paper and cite their sources.
May support extended VTE prophylaxis with betrixaban in selected medical patients; leaves open optimal duration and broader applicability.
Betrixaban is the first and only oral once-daily factor Xa inhibitor, approved by the FDA under Priority Review in June 2017, for extended prophylaxis of VTE in acutely ill medical patients.It has been approved based on data from a multinational APEX study that included 7513 patients at 460 sites.A benefit of betrixaban was observed in patients with an elevated d-dimer level or an age of at least 75 years, and in the overall population.Major bleeding was not statistically different between groups in the overall safety population.Overall, currently available data suggest that betrixaban is a safe and effective option for extended duration VTE prophylaxis in medically ill patients at risk for VTE during their transition from hospital to home.
No takes yet. Share an insight, caveat, or question.
Ohoud S. Almalki (2017) conducted a review in Acute medical illness at risk for venous thromboembolism (n=7,513). Betrixaban vs. Enoxaparin 40 mg daily was evaluated on Composite of asymptomatic proximal DVT between day 32 and day 47, symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism, or death from VTE between day 1 and day 42 (RR 0.76, 95% CI 0.63-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: